Mankind Pharma announced its audited financial results for the quarter and year ended March 31, 2026. The company reported a consolidated revenue of ₹3,442.93 crore for Q4 and ₹14,277.64 crore for the full financial year. Key developments include the re-appointment of a Whole-Time Director, an additional investment of ₹500 crore in a wholly-owned subsidiary, and a strategic decision by top management to forgo executive commissions to strengthen cash reserves.
Financial Performance Overview
For the quarter ended March 31, 2026, Mankind Pharma achieved a consolidated revenue of ₹3,442.93 crore, with a consolidated net profit for the period attributable to equity holders of ₹554.35 crore. On an annual basis, the company reported total consolidated revenue of ₹14,277.64 crore and a consolidated net profit of ₹1,912.93 crore for the full financial year ended March 31, 2026.
Strategic Investments and Corporate Governance
The Board of Directors has approved an additional investment of up to ₹500 crore in Mankind Medicare Private Limited, a wholly-owned subsidiary, to support capacity expansion and the development of a new manufacturing facility. Furthermore, the company has formally re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for a new 5-year term, effective September 23, 2026.
Management Commitment to Cash Position
In a significant move to bolster the company’s financial flexibility for future business expansion, the Executive Chairman Mr. Ramesh Juneja, Vice Chairman & Managing Director Mr. Rajeev Juneja, and CEO & Whole Time Director Mr. Sheetal Arora have decided to waive their commission for the 2025-26 financial year. This decision highlights the leadership’s focus on maintaining a robust cash position as the company pursues growth opportunities.
Operational Changes
The company also noted the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, effective from the close of business on May 31, 2026. Mankind Pharma continues to maintain a strong focus on its core pharmaceutical operations, reaffirming its commitment to operational excellence and sustainable growth.
Source: BSE
